EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase IV)

A randomised, crossover trial exploring the patient perspective and effectiveness of biosimilar adalimumab transition: IBD reference and biosimilar adalimumab cross over study (iBaSS)

David Young, Clare Harris, Sohail Rahmany, Inês Iria, João Gonçalves, Janet Addison, Justin Harvey, Sue Latter, Fraser Cummings

International Journal of Clinical Pharmacy · 2024

DOI: 10.1007/s11096-024-01739-5 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Clinical Pharmacy, 2024. Verfasst von David Young und 8 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy Department, University Hospital Southampton NHS Foundation Trust, Tremona Road, Southampton, SO16 6YD, UK. david.young@uhs.nhs.uk. Hauptthemen laut MEDLINE: Adalimumab, Biosimilar Pharmaceuticals, Cross-Over Studies, Patient Satisfaction. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Biogen Idec Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Patient satisfaction has been positively associated with adherence which is expected to impact outcomes. Although vital for successful implementation of biosimilar medicines, little is known about the patient perspective of transition. AIM: The aim of this study was to investigate clinical outcomes and patient experience of transitioning between reference adalimumab and a biosimilar (SB5). METHOD: iBaSS is a phase IV single-centre, prospective, randomised, single-blind, cross-over study in adult subjects with Crohn's disease. Participants, stable on adalimumab before consent, received 24 weeks of treatment with both reference adalimumab and SB5. The primary outcome was the proportion of patients maintaining baseline clinical status throughout each treatment period, with patients' perspective of disease control and treatment satisfaction assessed as secondary outcomes. RESULTS: A total of 112 participants, representative of the heterogeneous patient populations encountered in routine clinical practice, were enrolled. A similar proportion of participants maintained baseline clinical status through each treatment period: 81.8% with reference adalimumab and 79.5% with SB5. Patient reported outcomes (IBD-Control questionnaire (SB5: 15.5; reference adalimumab 15) and TSQM), adverse events and therapeutic drug monitoring remained consistent through both treatment periods, although a higher median injection pain VAS score was noted with SB5 (53/100 versus 6/100 with reference adalimumab). The number of switches undertaken in the study did not impact serum drug concentration or immunogenicity. CONCLUSION: This study, mimicking real world adalimumab transition, demonstrates that patients undertaking brand transition can be expected to have consistent clinical and satisfaction outcomes. CLINICAL TRIAL REGISTERED WITH EUDRACT: Number 2018-004967-30.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdalimumabBiosimilar PharmaceuticalsCross-Over StudiesPatient SatisfactionCrohn DiseaseHumansMaleFemaleAdultProspective StudiesSingle-Blind MethodMiddle AgedTreatment OutcomeYoung AdultAnti-Inflammatory AgentsPatient Reported Outcome Measures

Stichwörter der Autor:innen

AdalimumabBiosimilar pharmaceuticalsCrohn diseasePatient reported outcome measuresPatient satisfaction

Substanzen

AdalimumabBiosimilar PharmaceuticalsAnti-Inflammatory Agents

Autor:innen und Institutionen

  • Pharmacy Department, University Hospital Southampton NHS Foundation Trust, Tremona Road, Southampton, SO16 6YD, UK. david.young@uhs.nhs.uk.
  • Faculty of Medicine, University of Southampton, Southampton, UK. david.young@uhs.nhs.uk.
  • Faculty of Medicine, University of Southampton, Southampton, UK.
  • Department of Gastroenterology, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
  • Faculdade de Farmacia, Universidade Lisboa, Lisbon, Portugal.
  • Biogen UK, Maidenhead, UK.

Förderung

  • Biogen Idec Ltd.

Zitieren

APA

Young, D., Harris, C., Rahmany, S., Iria, I., Gonçalves, J., Addison, J., Harvey, J., Latter, S., & Cummings, F. (2024). A randomised, crossover trial exploring the patient perspective and effectiveness of biosimilar adalimumab transition: IBD reference and biosimilar adalimumab cross over study (iBaSS). International Journal of Clinical Pharmacy. https://doi.org/10.1007/s11096-024-01739-5

Vancouver

Young D, Harris C, Rahmany S, Iria I, Gonçalves J, Addison J, et al. A randomised, crossover trial exploring the patient perspective and effectiveness of biosimilar adalimumab transition: IBD reference and biosimilar adalimumab cross over study (iBaSS). International Journal of Clinical Pharmacy. 2024. doi:10.1007/s11096-024-01739-5

BibTeX
@article{Young2024,
  author = {Young, David and Harris, Clare and Rahmany, Sohail and Iria, Inês and Gonçalves, João and Addison, Janet and Harvey, Justin and Latter, Sue and Cummings, Fraser},
  title = {A randomised, crossover trial exploring the patient perspective and effectiveness of biosimilar adalimumab transition: IBD reference and biosimilar adalimumab cross over study (iBaSS)},
  journal = {International Journal of Clinical Pharmacy},
  year = {2024},
  doi = {10.1007/s11096-024-01739-5}
}
Kostenlos starten →